On May 19, 2017, the U.S. Centers for Disease Control and Prevention (CDC) published Immunization Practices Advisory Committee (ACIP)’s updated recommendations on use of Trumenba meningococcal serogroup B vaccine.

The ACIP recommended routine use of MenB vaccines among persons aged ≥10 years who were at increased risk for serogroup B meningococcal disease (Category A recommendation), including persons who had persistent complement component deficiencies; persons who had anatomic or functional asplenia; microbiologists who routinely were exposed to isolates of Neisseria meningitidis; and persons identified to be at increased risk because of a serogroup B meningococcal disease outbreak.

Adolescents and young adults aged 16–23 years may also be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B recommendation). Consistent with the original Food and Drug Administration (FDA) licensure for the MenB vaccines, ACIP recommended either a 3-dose series of MenB-FHbp or a 2-dose series of MenB-4C. Either MenB vaccine can be used when indicated; however, they are not interchangeable, and the same product must be used for all doses.